• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Xenon Pharmaceuticals Inc. - Product Pipeline Review - Q4 2010 Product Image

Xenon Pharmaceuticals Inc. - Product Pipeline Review - Q4 2010

  • ID: 1446457
  • November 2010
  • 45 pages
  • GlobalData

Xenon Pharmaceuticals Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Xenon Pharmaceuticals Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Xenon Pharmaceuticals Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Xenon Pharmaceuticals Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Xenon Pharmaceuticals Inc. Snapshot
Xenon Pharmaceuticals Inc. Overview
Key Information
Key Facts
Xenon Pharmaceuticals Inc. – Research and Development Overview
Key Therapeutic Areas
Xenon Pharmaceuticals Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Xenon Pharmaceuticals Inc. – Pipeline Products Glance
Xenon Pharmaceuticals Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Xenon Pharmaceuticals Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Xenon Pharmaceuticals Inc. – Drug Profiles
XEN 402
Product Description
Mechanism of Action
R&D Progress
XPF-001
Product Description
Mechanism of Action
R&D Progress
XEN 402
Product Description
Mechanism of Action
R&D Progress
ABCA1
Product Description
Mechanism of Action
R&D Progress
DMT1 inhibitors
Product Description
Mechanism of Action
R&D Progress
Drug for CVD
Product Description
Mechanism of Action
R&D Progress
Stearoyl-CoA Desaturase-1 Drug Development Program
Product Description
Mechanism of Action
R&D Progress
Hemojuvelin Inhibitors
Product Description
Mechanism of Action
R&D Progress
Xenon Pharmaceuticals Inc. – Pipeline Analysis
Xenon Pharmaceuticals Inc. – Pipeline Products by Therapeutic Class
Xenon Pharmaceuticals Inc. Pipeline Products By Target
Xenon Pharmaceuticals Inc. – Pipeline Products by Molecule Type
Xenon Pharmaceuticals Inc. – Recent Pipeline Updates
Xenon Pharmaceuticals Inc. - Dormant Projects
Xenon Pharmaceuticals Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Aug 17, 2010: Xenon Initiates Phase II Clinical Trial Of XEN 402 In Post Herpetic Neuralgia Patients
Dec 07, 2006: Xenon Enters Into Anemia Collaboration With Roche
Oct 03, 2006: Xenon And Takeda Announce Agreement To Develop And Commercialize XEN401 For Pain In Japan And Certain Asian Countries
Sep 20, 2004: Xenon And Novartis Sign Drug Development Deal For Obesity And Metabolic Disorders
Financial Deals Landscape
Xenon Pharmaceuticals Inc., Deals Volume Summary, 2004 to YTD 2010
Xenon Pharmaceuticals Inc., Deals Summary By Region, 2004 to YTD 2010
Xenon Pharmaceuticals Inc., Deals Summary, 2004 to YTD 2010
Xenon Pharmaceuticals Inc. Detailed Deal Summary
Venture Financing
Xenon Pharmaceuticals Secures $31 Million In Financing
Xenon Enters Into Research Agreement With Roche
Takeda Pharmaceutical Enters Into An Agreement With Xenon
Licensing Agreements
Xenon Pharmaceuticals Enters Into Cardiovascular Disease Collaboration With Merck
Xenon Enters Into Licensing Agreement With Novartis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS